Get started
Author

Mélanie Desbois

Observed names: Desbois, Melanie, Desbois, Mélanie, M Desbois, M. Desbois, Melanie Desbois
Observed institutions: Université Paris-Sud, Roche (United States), Centre National de la Recherche Scientifique, Inserm, Institut Pasteur, The University of Western Australia, Genentech, Université Paris-Saclay, Institut Gustave Roussy, Juntendo University, Sorbonne Paris Cité, Hôpital de la Conception, Immunocore (United Kingdom), IGM Biosciences (United States), Paris Cardiovascular Research Center, Institut Cochin, Centre de Recherche en Cancérologie de Marseille, Université Paris Descartes, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse, Fondation Gustave Roussy
ORCID: 0000-0001-5503-8821
Observed ORCID: 0000-0001-5503-8821
OpenAlex ID: A5012214419
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
2020 · Clélia Coutzac, Jean-Mehdi Jouniaux, et al. · Nature Communications · 544
PDF
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer
2021 · Milena Hornburg, Mélanie Desbois, et al. · Cancer Cell · 396
PDF
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
2011 · Magali Terme, Evelyn Ullrich, et al. · Cancer Research · 395
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
2013 · Sylvie Rusakiewicz, Michaela Semeraro, et al. · Cancer Research · 324
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
2021 · Mélanie Desbois, Yulei Wang · Immunological Reviews · 228
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer
2020 · Mélanie Desbois, Akshata R. Udyavar, et al. · Nature Communications · 215
PDF
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
2015 · Dalil Hannani, Marie Vétizou, et al. · Cell Research · 170
PDF
Erratum: Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
2015 · Dalil Hannani, Marie Vétizou, et al. · Cell Research · 135
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
2012 · Magali Terme, Evelyn Ullrich, et al. · Cancer Research · 128
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
2016 · Mélanie Desbois, Pauline Le Vu, et al. · The Journal of Immunology · 65
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
2020 · Mélanie Desbois, Coralie Béal, et al. · Journal for ImmunoTherapy of Cancer · 47
PDF
Natural killer cells in non-hematopoietic malignancies
2012 · Mélanie Desbois, Sylvie Rusakiewicz, et al. · Frontiers in Immunology · 38
PDF
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+NK cell levels correlate with disease outcome
2013 · Nathalie Chaput, Caroline Flament, et al. · OncoImmunology · 33
Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
2020 · Julia Delahousse, Charles Skarbek, et al. · Journal for ImmunoTherapy of Cancer · 7
PDF
Lever la tolérance immunitaire en cancérologie
2015 · Mélanie Desbois, Stéphane Champiat, et al. · Bulletin du Cancer · 7
IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
2025 · Mélanie Desbois, Thierry Giffon, et al. · Cancer Immunology Research · 6
PDF
Abstract 1068: Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity
2022 · Beatrice T. Wang, Melanie Desbois, et al. · Cancer Research · 3
Abstract 1899: Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models
2024 · Mélanie Desbois, Susan E. Calhoun, et al. · Cancer Research · 2
959 Tebentafusp controls disease and prolongs survival by increasing the T cell: tumor cell ratio, activating T cells and inhibiting tumor proliferation in metastatic uveal melanoma patients
2025 · Adel Benlahrech, James Clubley, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 5660: IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell mediated cytotoxicity of PD-L1-positive tumor cells
2023 · Thierry D. Giffon, Melanie Desbois, et al. · Cancer Research · 1
711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
2021 · Thierry Giffon, Melanie Desbois, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 52: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity
2021 · Beatrice T. Wang, Tasnim Kothambawala, et al. · Cancer Research · 1
Metadata and data associated with the published article: Systemic Short Chain Fatty Acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
2020 · Coutzac, Clélia, Jean-Medhi Jouniaux, et al. · Figshare · 1
Reactive stroma mediates CD8+ T cell spatial distribution and function in ovarian cancer
2017 · Y. Wang, L. Ryner, et al. · Annals of Oncology · 1
PDF
Effect of IL7 on ImmTAC-mediated killing by T cells in vitro and T-cell fitness in patients.
2026 · Joseph J. Sacco, Anna Broomfield, et al. · Journal of Clinical Oncology
PDF
Works count: 73
Citation count: 2,749
H-index: 13
I10-index: 13
Year
Topic
Type